| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Diphtheria + pertussis + tetanus + Haemophilus influenzae type b vaccine |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
2 |
| Haemophilus influenzae Type b vaccine |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Haemophilus influenzae Type b (Hib)/diphtheria/tetanus/pertussis vaccine vial+prefilled syringe |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
2 |
| Haemophilus influenzae Type b (Hib)/diphtheria/tetanus/pertussis vaccine prefilled syringe |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
2 |
| Haemophilus influenzae Type b (Hib)/diphtheria/tetanus/pertussis vaccine vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
2 |
| Haemophilus influenzae Type b vaccine injection (pdr for recon)+diluent |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae b vaccine |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
3 |
| Diphtheria/tetanus/pertussis/poliomyelitis/Haemophilus influenzae b vaccine 0.5mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
|
| Haemophilus b polysaccharide conjugate (diphtheria toxoid conjugate) vaccine |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Haemophilus b oligosaccharide conjugate(diphtheria CRM>197< protein conjugate) vaccine |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Diphtheria and tetanus toxoid + haemophilus b conjugate vaccine 0.6ml/0.5ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
|
| Diphtheria and tetanus toxoid + haemophilus b conjugate vaccine 7.5ml/5ml (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
|
| Haemophilus b polysaccharide + tetanus toxoid 10mcg/24mcg |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
|
| Diphtheria and tetanus toxoid 0.5vial/haemophilus b conjugate injection suspension vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
|
| Administration of first dose of vaccine product containing only Haemophilus influenzae type b antigen (procedure) |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Administration of second dose of vaccine product containing only Haemophilus influenzae type b antigen (procedure) |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Administration of third dose of Haemophilus influenzae type b vaccine |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen (procedure) |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Haemophilus influenzae Type B vaccine poisoning |
Causative agent (attribute) |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Accidental haemophilus influenzae Type B vaccine poisoning |
Causative agent (attribute) |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Intentional haemophilus influenzae Type B vaccine poisoning |
Causative agent (attribute) |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Haemophilus influenzae Type B vaccine poisoning of undetermined intent |
Causative agent (attribute) |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Adverse reaction to component of vaccine product containing Haemophilus influenzae type b antigen (disorder) |
Causative agent (attribute) |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Allergy to Haemophilus influenzae type b vaccine |
Causative agent (attribute) |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
|
| Administration of vaccine product containing only Haemophilus influenzae type b antigen (procedure) |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Haemophilus influenzae type b + Meningococcal group C vaccine |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Haemophilus influenzae Type b + recombinant hepatitis B virus vaccine |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Administration of third dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Haemophilus influenzae type b 7.5micrograms/recombinant hepatitis B virus surface antigen 5micrograms injection solution 0.5mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
|
| Haemophilus influenzae Type b + tetanus vaccine |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Haemophilus b polysaccharide 10micrograms/tetanus toxoid 30micrograms powder for injection solution vial + diluent |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
|
| Diphtheria toxoid 30 iu/tetanus toxoid 40 iu/acellular pertussis 25micrograms/recombinant hepatitis B virus surface antigen 10micrograms/inactivated poliomyelitis injection solution 0.5mL prefilled syringe |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
|
| Haemophilus influenzae type b 10micrograms/diphtheria toxoid 30 iu/tetanus toxoid 40 iu/pertussis 25micrograms/recombinant hepatitis B virus surface antigen 10micrograms/inactivated poliomyelitis injection solution 0.5mL prefilled syringe |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
|
| Diphtheria + tetanus + pertussis + poliomyelitis + recombinant hepatitis B virus + recombinant haemophilus influenzae type B vaccine |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
3 |
| Administration of fourth dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Administration of first dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Administration of vaccine product containing only Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Administration of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Administration of Haemophilus influenzae type b and meningitis C vaccine |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Diphtheria + tetanus + haemophilus influenzae type b vaccine |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
2 |
| Administration of Haemophilus influenzae type b and meningitis C vaccine |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Administration of fourth dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
2 |
| Administration of first dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
2 |
| Administration of vaccine product containing only Haemophilus influenzae type b antigen (procedure) |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Administration of second dose of vaccine product containing only Haemophilus influenzae type b antigen (procedure) |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
2 |
| Administration of vaccine product containing only Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
2 |
| Administration of first dose of vaccine product containing only Haemophilus influenzae type b antigen (procedure) |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Administration of third dose of Haemophilus influenzae type b vaccine |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Administration of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
2 |
| Administration of third dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Human poliovirus antigens (procedure) |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
2 |
| Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen (procedure) |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Administration of second dose of vaccine product containing only Haemophilus influenzae type b antigen (procedure) |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Administration of first dose of vaccine product containing only Haemophilus influenzae type b antigen (procedure) |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Administration of vaccine product containing only Haemophilus influenzae type b antigen (procedure) |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Administration of third dose of Haemophilus influenzae type b vaccine |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen (procedure) |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Allergy to Haemophilus influenzae type b vaccine |
Causative agent (attribute) |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine/Hepatitis B Surface Antigen Vaccine |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Administration of second dose of vaccine product containing only Haemophilus influenzae type b and Neisseria meningitidis serogroup C antigens (procedure) |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
4 |
| Administration of first dose of Haemophilus influenzae type b and meningitis C vaccine |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
4 |
| Haemophilus b polysaccharide 10micrograms/tetanus toxoid 30micrograms powder for conventional release solution for injection vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
|
| Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Hepatitis B virus antigens (procedure) |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
5 |
| Administration of third dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Hepatitis B virus antigens (procedure) |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Administration of first dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
3 |
| Administration of second dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Hepatitis B virus antigens (procedure) |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
3 |
| Haemophilus influenzae type b 7.5micrograms/recombinant hepatitis B virus surface antigen 5micrograms injection solution 0.5mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
2 |
| Haemophilus b polysaccharide 10micrograms/tetanus toxoid 30micrograms powder for conventional release solution for injection vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Vaccination for diphtheria, pertussis, tetanus, poliomyelitis, Hepatitis B virus and Haemophilus influenzae type b |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
3 |
| Haemophilus influenzae type b 10micrograms/diphtheria toxoid 30 iu/tetanus toxoid 40 iu/pertussis 25micrograms/recombinant hepatitis B virus surface antigen 10micrograms/inactivated poliomyelitis injection solution 0.5mL prefilled syringe |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
1 |
| Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b antigens (procedure) |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
2 |
| Diphtheria toxoid 30 iu/tetanus toxoid 40 iu/acellular pertussis 25micrograms/recombinant hepatitis B virus surface antigen 10micrograms/inactivated poliomyelitis injection solution 0.5mL prefilled syringe |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
2 |
| Administration of vaccine product containing only Haemophilus influenzae type b and Hepatitis B virus antigens (procedure) |
Direct substance |
False |
Haemophilus influenzae type b vaccine |
Inferred relationship |
Some |
2 |
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]